Global Longlife Hospital and Research Ltd (GLHRL) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Global Longlife Hospital and Research Ltd ₹19.32, price ₹12.15, upside +59.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
53‑month range ₹9.47 – ₹135.35 · fair‑value band ₹12.75 – ₹24.15 · the ₹12.15 price screens below the ₹19.32 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Global Longlife Hospital and Research in your weekly email
Every Wednesday you see whether Global Longlife Hospital and Research is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India.
Show more
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India. It offers medical services, such as oncology, ophthalmology, allergy and immunology, pain management, pulmonology, anaesthesiology, cardiology, dermatology, critical care, diabetes and endocrinology, GI medicine, gynecology, infectious disease, nephrology, and neurology; and surgical services, including CVTS, joint replacement orthopaedics, spine surgery, general surgery, onco surgery, GI surgery, neurosurgery, ENT, plastic surgery, trauma centre, urology, laparoscopic surgery, gynaecology, dental surgery, and vascular surgery. The company also provides radiology services consisting of mammography, CT scan, X-ray, ultrasound, endoscopy, and sonography; pathology services, including microbiology, biochemistry, clinical pathology, cyto pathology, haematology, and serology; and other services comprising dialysis, pharmacy, ambulance, dietary, and physiotherapy services. Global Longlife Hospital and Research Limited was Incorporated in 2012 and is based in Ahmedabad, India.
Stock analysis
Global Longlife Hospital and Research Ltd (GLHRL) currently trades at ₹12.15, while our model-based Fair Value estimate is ₹19.32, implying the stock looks roughly 37.1% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹12.75 (bear) to ₹24.15 (bull), the price of ₹12.15 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Global Longlife Hospital and Research Ltd reported revenue of ₹0 in FY2026 versus ₹328M in FY2022. Reported net income was −₹17.2M in FY2026.
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 59%, GLHRL screens cheaper than that median.
Fair Value models
Bear ₹12.75Fair Value ₹19.32Bull ₹24.15
Price ₹12.15 · Upside +59.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−95.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−74.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.4% (2021) → −803.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Global Longlife Hospital and Research Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 248 stocks
Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+59.0% · Top 25%
Profitability
Return on assets−2.5% · Bottom 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Global Longlife Hospital and Research Ltd Fair Value". https://www.fairvalue-calculator.com/stock/GLHRL
Frequently asked questions
Is Global Longlife Hospital and Research Ltd (GLHRL) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹19.32 versus a price of ₹12.15, about +59% upside (undervalued).
What is the fair value of GLHRL?
Our model-based fair value for Global Longlife Hospital and Research Ltd is ₹19.32 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹12.15.
What is the quality score of GLHRL?
Global Longlife Hospital and Research Ltd has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Global Longlife Hospital and Research Ltd (GLHRL)?
Our model-based price target is the fair value of ₹19.32 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario ₹12.75, optimistic scenario ₹24.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Global Longlife Hospital and Research Ltd stock forecast for 2026?
Our models put fair value at ₹19.32, about +59% upside versus a price of ₹12.15 (undervalued). Cautious scenario ₹12.75, optimistic scenario ₹24.15. The calculation is refreshed regularly with new filings.
What is the revenue of Global Longlife Hospital and Research Ltd (GLHRL)?
Global Longlife Hospital and Research Ltd reported trailing-twelve-month revenue of about ₹52.0K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Global Longlife Hospital and Research Ltd (GLHRL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Global Longlife Hospital and Research Ltd it is ₹19.32 per share (as of Oct 3, 2026), against a price of ₹12.15. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Global Longlife Hospital and Research Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, GLHRL trades below its calculated fair value: price ₹12.15, fair value ₹19.32, a gap of about +59% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GLHRL?
No. The price is what the market pays today (₹12.15); the fair value is what the company's own numbers justify (₹19.32). For Global Longlife Hospital and Research Ltd the two are ₹7.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Global Longlife Hospital and Research Ltd worth?
The market values Global Longlife Hospital and Research Ltd at about ₹128M (market capitalisation, as of Oct 3, 2026). Per share that is ₹12.15; our models calculate a fair value of ₹19.32 per share.
What do the bullish and bearish scenarios say about GLHRL?
Our models span a range for Global Longlife Hospital and Research Ltd: cautious scenario ₹12.75, base ₹19.32, optimistic ₹24.15 per share (as of Oct 3, 2026, price ₹12.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Global Longlife Hospital and Research Ltd (GLHRL)?
Balance-sheet figures for Global Longlife Hospital and Research Ltd (as of Oct 3, 2026): return on equity −6.8%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is GLHRL from its 52-week high?
Global Longlife Hospital and Research Ltd trades at ₹12.15, about 52% below its 52-week high of ₹25.48 and 28% above the low of ₹9.47 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹19.32 is for.
Which stocks are comparable to Global Longlife Hospital and Research Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Global Longlife Hospital and Research Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹12.15, calculated fair value ₹19.32 (+59%), Quality Score 65/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GLHRL calculated?
We run Global Longlife Hospital and Research Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹19.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Global Longlife Hospital and Research Ltd currently trades 37 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Global Longlife Hospital and Research Ltd (GLHRL)?
The closing price on Oct 1, 2026 was ₹12.15. Our model-based fair value is ₹19.32, about +59% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Global Longlife Hospital and Research Ltd right now?
The price is below even our cautious bear case (₹12.75). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (₹12.75 to ₹24.15) leaves room in how you read the outcome.
Key figures of Global Longlife Hospital and Research Ltd
How large is the market capitalisation of Global Longlife Hospital and Research Ltd (GLHRL)?
The market capitalisation of Global Longlife Hospital and Research Ltd is ₹128M (≈ $1.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Global Longlife Hospital and Research Ltd (GLHRL)?
Earnings per share at Global Longlife Hospital and Research Ltd are ₹−1.64. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Global Longlife Hospital and Research Ltd (GLHRL)?
The return on equity (ROE) of Global Longlife Hospital and Research Ltd is −6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Global Longlife Hospital and Research Ltd (GLHRL)?
On an EBIT basis the return on assets of Global Longlife Hospital and Research Ltd is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Global Longlife Hospital and Research Ltd (GLHRL)?
The operating margin of Global Longlife Hospital and Research Ltd is −19,094% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Global Longlife Hospital and Research Ltd (GLHRL)?
Earnings per share at Global Longlife Hospital and Research Ltd are growing +20.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Global Longlife Hospital and Research Ltd (GLHRL) generate?
The free cash flow of Global Longlife Hospital and Research Ltd is −₹45.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Global Longlife Hospital and Research Ltd (GLHRL) carry?
The net debt of Global Longlife Hospital and Research Ltd is ₹124M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Global Longlife Hospital and Research Ltd in the live analysis
One click puts Global Longlife Hospital and Research Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
